Investor

CONTACT DETIALS

2175 Visionary Way
Suite 1160
Fishers, IN 46038

(317) 286-6788

ceo@acrobiomedicalco.com

DESCRIPTION

Acro Biomedical is in the business of developing and marketing nutritional products that promote wellness and a healthy lifestyle. All of the Company’s sales to date have been sales of cordyceps related products and, commencing in the second quarter of the year ended September 30, 2018, metallothionein MT-3 elizer. The Company may also seek to market other products which it sees as complimentary to its present products and conduct research and development on our own proprietary products based on cordyceps sinensis.

More >>


Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report JUN 30, 2019
CIK 0001622996
Fiscal Year End 9/30
OTC Marketplace OTCQX
Profile Data
SIC – Industry Classification 7900 – Services-Amusement & Recreation Services
Incorporated In: NV, USA, 2014
Shell: No
Employees 1 as of 12/24/2018
Company Officers/Contacts
Pao-Chi Chu President, CEO, CFO
Shih-To Li Advisor
Cheng-Hsiang Kao Consultant
Company Directors

Pao-Chi Chu

Service Providers
Accounting/Auditing Firm Securities Counsel
Prager Metis CPAs LLC Ellenoff Grossman & Schole LLP
15 Warren Street 1345 Avenue of the Americas
Suite 25 New York, NY 10105
Hackensack, NJ 07601  
Company Notes
  • Formerly=Killer Waves Hawaii, Inc. until 2-2017

ACBM Security Details

Share Structure
Market Cap 191,995,200 11/22/2019
Authorized Shares 100,000,000 11/18/2019
Outstanding Shares 47,760,000 11/18/2019
-Restricted 36,100,000 11/18/2019
-Unrestricted 11,660,000 11/18/2019
Held at DTC 575,000 11/18/2019
Float 11,660,000 01/24/2019
Par Value No Par Value  
Transfer Agent(s)

ClearTrust, LLC

Shareholders
Shareholders of Record 11 12/28/2018
Corporate Actions
  SPLIT DATE REC DATE PAY DATE
Dividends & Splits 05/22/2017 05/18/2017 05/19/2017
Dividends are not adjusted for stock splits.
Security Notes
  • Capital Change=shs increased by 3 for 1 split. Ex-date=05/22/2017. Rec date=05/18/2017. Pay date=05/19/2017.
Short Selling Data
Short Interest 100 (-45.67%) 10/31/2019
Significant Failures to Deliver     No